Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Isofol Medical

Isofol Medical

Send subscription Close

Isofol Medical AB is a Swedish biotech company with six FTEs listed on Nasdaq Stockholm, developing arfolitixorin, an active folate designed to enhance the efficacy of standard 5-FU chemotherapy in metastatic colorectal cancer. The company aims to replace leucovorin, an inactive folate, with arfolitixorin, which Isofol believes may improve the tumour-killing effect of 5-FU by delivering the active metabolite directly.

Isofol faces development and regulatory risks in particular, as the success of arfolitixorin is entirely dependent on future clinical data. Furthermore, securing and sustaining partners poses a risk, as well as achieving a successful commercialisation of the drug.

Financials

2025 2026e 2027e
Sales 0 0 66
Sales growth (%) N/A N/A N/A
EBITDA -59 -69 -14
EBITDA margin (%) N/A N/A -21,7
EBIT adj. -59 -69 -14
EBIT adj. margin (%) N/A N/A -21,7
Pretax profit -57 -67 -13
EPS -0,26 -0,2 -0,04
EPS growth (%) -4,2 -21,8 -81,9
EPS adj. -0,26 -0,2 -0,04
DPS 0 0 0
EV/EBITDA (x) -1,9 -2,4 -11,3
EV/EBIT adj. (x) -1,9 -2,4 -11,3
P/E (x) N/A N/A N/A
P/E adj. (x) N/A N/A N/A
EV/sales (x) N/A N/A 2,46
FCF yield (%) -36,5 -29 -5,3
Le. adj. FCF yld. (%) -36,5 -29 -5,3
Dividend yield (%) 0 0 0
Net IB debt/EBITDA (x) 0,7 0,9 6,1
Le. adj. ND/EBITDA (x) 0,7 0,9 6,1
2025 2026e 2027e
Sales 0 0 66
COGS 0 0 0
Gross profit 0 0 66
Other operating items -59 -69 -81
EBITDA -59 -69 -14
Depreciation and amortisation 0 0 0
of which leasing depreciation 0 0 0
EBITA -59 -69 -14
EO Items 0 0 0
Impairment and PPA amortisation 0 0 0
EBIT -59 -69 -14
Net financial items 2 3 1
Pretax profit -57 -67 -13
Tax 0 0 0
Net profit -57 -67 -13
Minority interest 0 0 0
Net profit discontinued 0 0 0
Net profit to shareholders -57 -67 -13
EPS -0,26 -0,2 -0,04
EPS adj. -0,26 -0,2 -0,04
Total extraordinary items after tax 0 0 0
Leasing payments 0 0 0
Tax rate (%) 0 0 0
Gross margin (%) N/A N/A 100
EBITDA margin (%) N/A N/A -21,7
EBITA margin (%) N/A N/A -21,7
EBIT margin (%) N/A N/A -21,7
Pre-tax margin (%) N/A N/A -19,9
Net margin (%) N/A N/A -19,9
Growth Rates y-o-y N/A N/A N/A
Sales growth (%) N/A N/A N/A
EBITDA growth (%) 25,3 17,4 -79,2
EBITA growth (%) 25,3 17,4 -79,2
EBIT growth (%) 25,3 17,4 -79,2
Net profit growth (%) 31,3 16,9 -80,2
EPS growth (%) -4,2 -21,8 -81,9
Profitability N/A N/A N/A
ROE (%) -62,4 -70,9 -17,2
ROE adj. (%) -62,4 -70,9 -17,2
ROCE (%) -62 -70,4 -17,1
ROCE adj. (%) -62 -70,4 -17,1
ROIC (%) -263,5 -163,5 -585,9
ROIC adj. (%) -263,5 -163,5 -585,9
Adj. earnings numbers N/A N/A N/A
EBITDA adj. -59 -69 -14
EBITDA adj. margin (%) N/A N/A -21,7
EBITDA lease adj. -59 -69 -14
EBITDA lease adj. margin (%) N/A N/A -21,7
EBITA adj. -59 -69 -14
EBITA adj. margin (%) N/A N/A -21,7
EBIT adj. -59 -69 -14
EBIT adj. margin (%) N/A N/A -21,7
Pretax profit Adj. -57 -67 -13
Net profit Adj. -57 -67 -13
Net profit to shareholders adj. -57 -67 -13
Net adj. margin (%) N/A N/A -19,9
2025 2026e 2027e
EBITDA -59 -69 -14
Goodwill 0 0 0
Net financial items 2 3 1
Other intangible assets 0 0 0
Paid tax 0 0 0
Tangible fixed assets 0 0 0
Non-cash items 0 0 0
Right-of-use asset 0 0 0
Cash flow before change in WC -57 -67 -13
Total other fixed assets 0 0 0
Change in working capital 1 0 0
Fixed assets 0 0 0
Operating cash flow -56 -67 -13
Inventories 0 0 0
Capex tangible fixed assets 0 0 0
Receivables 2 2 2
Capex intangible fixed assets 0 0 0
Other current assets 82 42 2
Acquisitions and Disposals 0 0 0
Cash and liquid assets 43 61 88
Free cash flow -56 -67 -13
Total assets 126 105 92
Dividend paid 0 0 0
Shareholders equity 105 83 70
Share issues and buybacks 84 47 0
Minority 0 0 0
Leasing liability amortisation 0 0 0
Total equity 105 83 70
Other non-cash items -81 38 40
Long-term debt 1 1 1
Pension debt 0 0 0
Convertible debt 0 0 0
Leasing liability 0 0 0
Total other long-term liabilities 0 0 0
Short-term debt 0 0 0
Accounts payable 2 2 2
Other current liabilities 19 19 19
Total liabilities and equity 126 105 92
Net IB debt -42 -61 -88
Net IB debt excl. pension debt -42 -61 -88
Net IB debt excl. leasing -42 -61 -88
Capital employed 106 84 71
Capital invested 62 22 -18
Working capital 62 22 -18
EV breakdown N/A N/A N/A
Market cap. diluted (m) 154 230 251
Net IB debt adj. -42 -61 -88
Market value of minority 0 0 0
Reversal of shares and participations 0 0 0
Reversal of conv. debt assumed equity N/A N/A N/A
EV 111 169 163
Total assets turnover (%) 0 0 67,5
Working capital/sales (%) N/A N/A 3,7
Financial risk and debt service N/A N/A N/A
Net debt/equity (%) -40,5 -73 -125
Net debt / market cap (%) -27,6 -26,4 -34,9
Equity ratio (%) 83 79,5 76,5
Net IB debt adj. / equity (%) -40,5 -73 -125
Current ratio 6,05 5,02 4,39
EBITDA/net interest 28,4 25,5 11,8
Net IB debt/EBITDA (x) 0,7 0,9 6,1
Net IB debt/EBITDA lease adj. (x) 0,7 0,9 6,1
Interest coverage 57079 N/A N/A
2025 2026e 2027e
Shares outstanding adj. 221 331 361
Diluted shares adj. 221 331 361
EPS -0,26 -0,2 -0,04
Dividend per share 0 0 0
EPS adj. -0,26 -0,2 -0,04
BVPS 0,47 0,25 0,19
BVPS adj. 0,47 0,25 0,19
Net IB debt/share -0,19 -0,18 -0,24
Share price 0,7 0,7 0,7
Market cap. (m) 154 230 251
Valuation N/A N/A N/A
P/E (x) N/A N/A N/A
EV/sales (x) N/A N/A 2,5
EV/EBITDA (x) -1,9 -2,4 -11,3
EV/EBITA (x) -1,9 -2,4 -11,3
EV/EBIT (x) -1,9 -2,4 -11,3
Dividend yield (%) 0 0 0
FCF yield (%) -36,5 -29 -5,3
Le. adj. FCF yld. (%) -36,5 -29 -5,3
P/BVPS (x) 1,47 2,76 3,58
P/BVPS adj. (x) 1,47 2,76 3,58
P/E adj. (x) N/A N/A N/A
EV/EBITDA adj. (x) -1,9 -2,4 -11,3
EV/EBITA adj. (x) -1,9 -2,4 -11,3
EV/EBIT adj. (x) -1,9 -2,4 -11,3
EV/CE (x) 1,1 2 2,3
Investment ratios N/A N/A N/A
Capex/sales (%) N/A N/A 0
Capex/depreciation N/A N/A N/A
Capex tangibles / tangible fixed assets N/A N/A N/A
Capex intangibles / definite intangibles N/A N/A N/A
Depreciation on intang / def. intang N/A N/A N/A
Depreciation on tangibles / tangibles N/A N/A N/A

Equity research

Read earlier research

Main shareholders -

Main shareholders Share capital % Voting shares % Verified